CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sezary syndrome: the Sezary signature genes, FCRL3, Tox, and miR-214. by Benoit, Bernice M. et al.
 CD164 identifies CD4+ T cells highly expressing genes associated with 
malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, 
and miR-214 
 
 
Bernice M. Benoit1; Neha Jariwala1 ; Geraldine O’Connor2 ; Landon K. Oetjen3,8 ; Timothy M. 
Whelan3 ; Adrienne Werth1  ; Andrea B. Troxel4 ; Hélène Sicard5 ;Lisa Zhu1 ;Christopher Miller1 ; 
Junko Takeshita1; Daniel W. McVicar2 ; Brian S. Kim3,6,7,8 ; Alain H. Rook1 ; Maria Wysocka1 
 
1 Department of Dermatology, Perelman School of Medicine, 
University of Pennsylvania, 421 Curie Blvd, 1049 BRB, Philadelphia, PA 19104, USA 
2 National Cancer Institute, Cancer and Inflammation Program, Frederick, MD, USA 
3Division of Dermatology, Department of Medicine, Washington University, St. Louis, MO, USA 
4Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, 
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 
5 Innate Pharma, Research and Drug Development, Marseille, France 
6 Department of Anesthesiology, Washington University, St. Louis, MO, USA 
7 Department of Pathology and Immunology, Washington University, St. Louis, MO, USA 
8 The Division of Biology and Biomedical Sciences, Washington University, St. Louis, MO, USA 
 
Corresponding author; Maria Wysocka mwysocka@mail.med.upenn.edu 
 
 
 
 
 
 Abstract  
Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with 
a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis 
of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a 
biomarker(s) highly specific for malignant CD4+ T cells in SS patients has been a serious obstacle in 
making an early diagnosis. We recently demonstrated the high expression of CD164 on CD4+ T cells 
from Sézary syndrome patients with a wide range of circulating tumor burdens. To further 
characterize CD164 as a potential biomarker for malignant CD4+ T cells, CD164+ and CD164-CD4+ 
T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/ low tumor 
burden, B1–B0 stage, were assessed for the expression of genes reported to differentiate SS from 
normal controls, and associated with malignancy and poor prognosis. The expression of Sézary 
signature genes: T plastin, GATA-3, along with FCRL3, Tox, and miR-214, was significantly higher, 
whereas STAT-4 was lower, in CD164+ compared with CD164-CD4+ T cells. While Tox was highly 
expressed in both B2 and B1–B0 patients, the expression of Sézary signature genes, FCRL3, and 
miR214 was associated predominantly with advanced B2 disease. High expression of CD164 mRNA 
and protein was also detected in skin from CTCL patients. CD164 was co-expressed with KIR3DL2 
on circulating CD4+ T cells from high tumor burden SS patients, further providing strong support for 
CD164 as a disease relevant surface biomarker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-trafficking CD4+ T cells most 
commonly manifested as mycosis fungoides (MF) and Sézary syndrome (SS). Whereas mycosis 
fungoides are primarily an indolent disease restricted to the skin, with the presence of patches or 
plaques, Sezary syndrome represents a leukemic variant with erythroderma, circulating malignant 
CD4+ T cells and a significantly shorter life expectancy. Early diagnosis of SS is, therefore, key to 
achieving enhanced therapeutic responses [23]. The lack of a biomarker(s) highly specific for 
malignant CD4+ T cells in SS patients has been a serious obstacle in making an early diagnosis and 
in evaluating the extent of the disease, thereby prompting continuous attempts to find a CTCL specific 
marker. 
Currently, it is accepted that malignant CD4+ T cells in Sézary syndrome are a single TCRVβ clonal 
population with central memory phenotype, high expression of CCR4, and lack of CD26 [7, 12, 39, 
44]. At the transcriptional level, the expression of GATA-3, Twist 1, and Tox is increased, while the 
expression of STAT-4 is decreased in patients’ CD4+ T cells compared to healthy controls [13, 18, 
21, 38, 41]. In addition, the intracellular protein T plastin was found in CD4+ T cells from SS patients 
but not in normal controls [21]. GATA-3, T plastin, STAT-4, and CD26 were named ‘‘Sézary 
signature’’ genes, and differences between patients’ and healthy individuals’ in their expression in 
CD4+ T cells have aided in diagnosis of Sézary syndrome [33]. Recently, small, non-coding RNA 
molecules, microRNAs (miR-) were found to have potential diagnostic value in CTCL. 
Overexpression of several microRNAs, including miR-214 and miR-21, made it possible to 
distinguish CTCL and SS patients with a poor prognosis from benign disorders [3, 32]. The 
identification and isolation of malignant cells expressing the aforementioned genes critically depend 
on finding a cell-surface marker unique to malignant cells in CTCL. The presence of such 
 biomarker(s) will aid in diagnosis and monitoring of the disease as well as in designing effective 
treatments targeting malignant cells and sparing of normal immunocompetent cells. Several surface 
molecules, namely, NKp46, syndycan 4 (SD-4), ganglioside GD3 (CD60), mucin 1 (Muc 1), and 
CD158k/KIR3DL2, have been found to be highly expressed on CD4+ T cells from some SS patients 
compared with healthy controls [5, 9, 19, 36, 37]. SD-4, CD60, and Muc-1 molecules are also 
upregulated on activated normal CD4+ T cells [1, 8, 27]. Prior to its detection on CD4+ T cells from 
SS patients, KIR3DL2, a killer immunoglobulin-like receptor was mainly associated with a 
population of CD8+ T cells and NK cells in healthy controls. The report by Poszepszynska-Guine et 
al. which demonstrated high expression of KIR3DL2 on CD4+ T cells representing the malignant 
clonal cell population, provided an opportunity to utilize KIR3DL2 in diagnosis of SS [36]. 
Our studies focus on finding cell-surface marker (-s) unique to CTCL patients with varying tumor 
burdens in the circulation. We recently reported high expression of CD164 and FCRL3 on CD4+ T 
cells in Sézary syndrome patients [43]. CD164 is a sialomucin adhesion receptor that was originally 
demonstrated on a population of CD34+ hematopoietic progenitor cells, but recently has been shown 
in some human cancer cells, where it has been implicated to play a role in the development as well as 
metastasis of cancer [16, 26, 42]. Fc-receptor-like 3 (FCRL3) expression, originally associated with 
naturally occurring human T regulatory cells, was found by our group to correlate with SS progression 
[31, 43]. The expression of CD164 on CD4+ T cells correlated positively with a wide range of 
circulating tumor burdens, whereas FCRL3 expression was noted mainly in high tumor burden 
patients. The potential for CD164 to serve as a marker for malignant CD4+ T cells was underscored 
by the following findings: CD164 acquisition correlated with loss of CD26 expression and it was co-
expressed with a dominant TCRVβ; CD164+CD4+ T cells demonstrated the morphology of Sézary 
cells and were diminished or no longer detectable in patients who experienced clinical remission. 
In the present studies, we further addressed the specificity of CD164 as a marker of malignant cells. 
We used the level of expression of Sézary signature genes, along with FCRL3, Tox, miR-214, and 
miR-21 expression as an indication of malignancy in populations of CD164+- and CD164--circulating 
CD4+ T cells. The results demonstrate that the malignancy genes are predominantly associated with 
CD164+CD4+ T cells and that CD164 is also expressed in skin-residing CD41 T cells of CTCL 
patients. In addition, our results show the expression of both, CD164 and KIR3DL2 on CD4+ T cells 
in 82 % of SS patients. These results provide support for CD164 as a cell-surface biomarker for CD4+ 
T cells with a malignant phenotype in CTCL. 
Materials and methods 
Patients 
Patients were diagnosed on the basis of clinical, histopathologic, and immunohistologic criteria as 
previously defined [30]. Patients with erythroderma and circulating malignant T cells were diagnosed 
as B0, B1, or B2, according to criteria defined by Olsen et al.; all B2 patients were stage IVA1, and 
B0–B1 patients were stage III A–B [34]. Mycosis fungoides patients, with clinically and 
histologically defined skin lesions of patches, plaques, tumors, or erythroderma, but without blood 
involvement were diagnosed as stages IA through IIIA. Specimens were obtained from CTCL 
patients seen at the Cutaneous T-Cell Lymphoma Clinic and psoriasis patients seen at Psoriasis Clinic 
of the University of Pennsylvania. Atopic Dermatitis patients were seen in the Division of 
Dermatology in the Department of Medicine at the Washington University School of Medicine. 
Healthy control skin samples were obtained as residual healthy marginal skin from patients 
undergoing routine dermatologic surgery at the Department of Dermatology, University of 
Pennsylvania Health System. 
 All samples were collected in accordance with protocols approved by the University of 
Pennsylvania and Washington University Institutional Review Board, and studies were conducted 
according to the Declaration of Helsinki Principles. 
Flow cytometry 
To exclude the effect of treatment on the expression of different genes, peripheral blood mononuclear 
cells (PBMC) isolated from patients with no prior treatments were used in the studies. The cells were 
stained with fluorochrome-conjugated antibodies allowing the identification of live CD164+ and 
CD164-CD4+/CD3+ T cells. Antibodies were purchased from BD Biosciences (San Jose, CA), and 
the Live/Dead Fixable Aqua Dead Cell Stain Kit was purchased from Invitrogen (Grand Island, NY). 
Stained PBMC were sorted using BD FACS Aria II cell sorter. 
To assess the expression of CD158k/KIR3DL2 (clone MOG1-M-K322-13E4c, provided by Innate 
Pharma), 100ll of patient’s blood sample was incubated with antibodies against CD3, CD4, CD26, 
and KIR3DL2 in room temperature (RT) for 45 min. To assess the co-expression of CD164 and 
KIR3DL2, patient’s PBMC (1x106) were stained with anti-CD164 antibody plus antibodies indicated 
above followed by 45 min incubation in RT. In addition, KIR3DL2 expression on patients’ CD4+ T 
cells was tested using antibody DX31. DX31 antibody was the gift of Dr. Lewis Lanier, UCSF and 
was purified from the hybridoma by the UCSF Hybridoma Core Facility. PBMC were stained with 
biotinylated antibody DX31 and with antiCD3, CD4, and CD26 for 30 min at 4 C followed by 15 min 
incubation at 4 C with Streptavidin-APC. Both antibodies against KIR3DL2 generated similar results. 
Skin lymphocytes were isolated using a modified method described by Kim et al. [22]. Skin 
biopsies were stored in 0.08 % trypsin, overnight at 4C followed by 2 h incubation in a 37C/5 %CO2 
incubator with 0.125 mg/ml Libertase TL (Roche). Isolated cells were stained with fluorochrome-
conjugated antibodies to identify CD3/CD4 T cells expressing CD164. Cells were analyzed on an 
LSRII flow cytometer (Becton Dickenson, San Jose, CA) at the Flow Cytometry and Cell Sorting 
Core, Abramson Cancer Center, University of Pennsylvania. FlowJo software was used to analyze 
data (Tree Star, Ashland, OR). RNA isolation and quantitative real-time PCR 
To assess the expression of T plastin, Gata-3, STAT-4, FCRL3, and Tox on sorted CD164+/CD164-
CD4+ T cells, total RNA was extracted from sorted and normal CD41 T cells using the Qiagen RNeasy 
Mini Kit (Qiagen) according to the manufacturers’ instructions. For skin samples, total RNA was 
extracted from formalin-fixed paraffin embedded (FFPE) samples and normal tissue using the Qiagen 
RNeasy FFPE Kit and Fibrous Tissue Kit (Qiagen) following the manufacturers’ instructions. Single-
stranded cDNA was synthesized by reverse transcription of 40 nanograms of RNA from 
CD164+/CD164-CD4+ T cells and skin biopsies using the High Capacity RNA to cDNA Kit (Applied 
Biosystems) for further analysis. QRT-PCR was performed using Taqman gene expression assays 
(Applied Biosystems) with Taqman Gene Expression Master Mix (Applied Biosystems) according to 
the manufacturers’ instructions. Expression levels were normalized to b-actin and analyzed using the 
DDCT method. 
To evaluate expression of miR-214 and miR-21 in CD4+ T cells and skin biopsies, 10 nanograms 
of total RNA was reverse transcribed to cDNA using the Taqman microRNA Reverse Transcription 
Kit (Applied Biosystems) following their custom RT and preamplification protocols. QRT-PCR was 
performed with Taqman microRNA primers (Applied Biosystems) according to the manufacturers’ 
instructions. Samples always were run in triplicate on the Applied Biosystem 7500 Ral Time PCR 
System. Expression levels were normalized to U6 snRNA and analyzed using the DDCT method. 
  
 Results 
The expression of Sézary signature genes, FCRL3, Tox, and miR-214 is mainly associated 
with circulating CD164+CD4+ T cells in Sézary syndrome patients Sézary 
We assessed the expression of Sézary signature genes in sorted CD164+/CD164- CD4+ T cells. In 
addition, we evaluated expression of FCRL3 and Tox (Fig. 1). [31, 43]. Tox, a nuclear factor critically 
involved in CD4+ development in the thymus but downregulated on normal peripheral CD4+ T cells, 
was demonstrated in CD4+ T cells from CTCL patients and its high expression correlated with 
increased mortality [2, 6, 11, 29]. 
Patients’ PBMC were sorted into CD164+CD4+ and CD164-CD4+ T cells, and the expression of 
Sézary signature genes as well as FCRL3 and Tox was assessed by quantitative real-time PCR (qRT-
PCR). In patients defined as B2; stage IVA1, experiencing advanced disease and C50 % of CD26-
CD4+ T cells highly expressing CD164, the population of CD164+CD4+ T cells demonstrated a 
significant increase in mRNA expression of T plastin (1.4 fold), GATA-3 (1.3 fold), but 6.3 fold 
decrease in STAT-4 mRNA expression compared with CD164-CD4+ T cells. Similarly, FCRL3 and 
Tox mRNA expression was significantly higher in CD164+CD4+ T cells from B2 patients compared 
with CD164-CD4+ T cells (1.9 and 1.5 fold higher, respectively) (Fig. 1, upper panel). In patients with 
low tumor burden, B1–B0; stages III B–A, and B50 % CD26- CD164+CD4+ T cells, CD164+CD4+ T 
cells demonstrated a 4.4 fold higher expression of T plastin and 1.8 fold lower expression of STAT-
4 compared with CD164-CD4+ T cells (Fig. 1 lower panel). However, the differences between these 
two populations lacked statistical significance due to the variability between patients. An overall 
expression of T plastin in B1–B0 patients was several folds lower, whereas STAT-4 expression was 
higher compared with levels in B2 patients. The levels of GATA-3 expression in both CD164+ and 
CD164-CD4+ T cells were comparable to those in healthy controls. B1–B0 patients also demonstrated 
low levels of FCRL3 expression. Although a 2.2-fold increase in FCRL3 expression was observed in 
CD164+ compared with CD164-CD4+ T cells, it was not significant. Interestingly, the expression of 
Tox was significantly increased (2.9 fold) in CD164+CD4+ T cells compared with CD164-CD4+ T 
cells from B1 to B0, patients pointing to the potential association between CD164 and Tox expression 
in patients with a low-circulating burden of malignant cells (Fig. 1, lower panel). 
 
 
CD164 expression is increased in skin from CTCL patients 
To establish CD164 expression in skin-residing malignant cells, skin biopsies from patients 
diagnosed with SS, MF, atopic dermatitis (AD), psoriasis (PS), and healthy marginal skin from 
patients undergoing routine dermatologic surgery (HC) were assessed for CD164 mRNA expression. 
As shown in Fig. 2, the expression of CD164 mRNA in skin from SS and MF patients was 
significantly several fold increased (19.5 fold and 12.2 fold, respectively) compared with its level in 
skin from AD patients or control skin (left panel). A 5.3-fold increase in CD164 mRNA was noted in 
skin from psoriasis patients. T plastin mRNA was also increased in skin lesions of CTCL patients, as 
previously reported by other authors (data not shown) [25]. 
To determine if CD164 protein is expressed in skin CD4+ T cells, lymphocytes were isolated from 
skin biopsies of SS patients and healthy controls using the modified method described by Kim et al. 
[22]. Cells were stained with fluorochrome-conjugated antibodies and analyzed by flow cytometry to 
identify CD4+ T cells expressing CD164. As shown in Fig. 3a, 33.7 % of the CD4+ T cells from the 
skin of patients expressed CD164 compared with 9.7 % CD4+ T cells from normal skin. In Fig. 3b, a 
flow cytometry histogram shows CD164 expression on CD4+ T cells of a representative SS patient 
and control. 
 
 MiR-214 expression is significantly upregulated in circulating CD164+CD4+ T cells 
It has been reported that miR-214 and miR-21 are overexpressed in CD4+ T cells of SS patients with 
a poor prognosis [32]. We first determined that miR-214 was expressed in circulating CD4+ T cells 
of 89 % of patients, whereas miR-21 (data not shown) was detected only in 17 % of patients. This 
result prompted us to focus on miR214. MiR-214 expression was highly upregulated in CD4+ T cells 
from B2 patients, but only marginally upregulated in B1–B0 patients (Fig. 4a, b). Next, we 
determined the expression of miR-214 in sorted CD164+ and CD164-CD4+ T cells from B2 patients. 
As shown in Fig. 4c, miR-214 expression was significantly, 1.8 fold, upregulated in CD164+CD4+ T 
cells compared with CD164-CD4+ T cells. 
In contrast to circulating CD4+ T cells, miR-21 but not miR-214 expression was demonstrated in 
skin biopsies from both SS and MF, suggesting that the skin environment may promote the expression 
of different microRNAs (data not shown). 
CD164 and KIR3DL2 are co-expressed on CD4+ T cells from SS patients 
Since KIR3DL2 was demonstrated as a reliable cell-surface marker for Sézary cells, we examined 
the association between KIR3DL2 and CD164 expression on CD4+ T cells from SS patients [28, 36]. 
As shown in Fig. 5, CD164 and KIR3DL2 are expressed on patients’ CD4+ T cells and the level of 
expression correlates with the severity of disease. In B2 patients (Fig. 5a), with an average of 68.7 % 
of CD4+ T cells lacking CD26 expression, KIR3DL2 expression was demonstrated on 32.7 % of 
CD4+ T cells, whereas CD164 was present on 47.7 % of CD4+ T cells. Only 4 out of 31 B2 patients 
(13 %) showed no or B2 % of KIR3DL2 expression on their CD4+ T cells that were positive for 
CD164. In contrast, five out of ten B1–B0 patients (Fig. 5b) showed no expression of KIR3DL2. In 
the remaining five patients, KIR3DL2 expression on CD4+ T cells varied from 4.2 to 50.6 %. On 
average, 30.2 % of CD4+ T cells from B1 to B0 patients showed no expression of CD26, 25 % of 
CD4+ T cells expressed CD164, but only 9.5 % expressed KIR3DL2. Our results indicate that 
KIR3DL2 expression is mainly evident in patients with advanced B2 disease. Importantly, in patients 
expressing both molecules, CD164 and KIR3DL2 were predominantly co-expressed on the same 
CD4+ T cells (Fig. 5c). 
Vβ 
Discussion 
In our previous report, we showed that CD164 was coexpressed with a single dominant TCRVβ on 
CD26-CD4+ T cells and its expression correlated positively with a wide range of circulating tumor 
burdens in SS patients [43]. Our results were subsequently supported by studies of Guenova et al. 
confirming that CD164 is expressed on clonal malignant CD4+ T cells [14]. Based on this data, we 
have postulated that CD164 may serve as a positive cell-surface marker that distinguishes between 
normal and malignant CD4+ T cells in SS patients, particularly among patients, whose TCRVβ could 
not be defined by antibodies. Our current studies were designed to further examine the malignant 
status of CD164+CD4+ T cells by assessing the expression of genes reported to differentiate SS 
patients from healthy individuals and by examining the pattern of expression of CD164 and KIR3DL2 
on patients’ CD4+ T cells. 
We show that predominantly CD164+CD4+ T cells express genes associated with the Sézary 
signature phenotype. In accordance with this phenotype, the expression of T-plastin and the Th2-
associated transcription factor GATA-3 is significantly higher in CD164+CD4+ T cells compared with 
CD164-CD4+ T cells. As expected, the expression of STAT-4 is significantly lower in CD164+ 
compared to CD164-CD4+ T cells. Furthermore, the expression of FCRL3, Tox, and miR-214 is also 
higher in CD164+CD4+ T cells in comparison with CD164-CD4+ T cells. We demonstrate the presence 
 of CD164 mRNA and protein in skin-residing CD4+ T cells from SS patients. Levels of CD164 
mRNA are significantly increased in skin lesions from SS and MF, compared to AD, PS, and normal 
skin. Interestingly, low levels of CD164 expression were demonstrated in skin biopsies from patients 
with psoriasis, however, significantly lower, compared with SS or MF patients (3.6 fold, p= 0.006 
and 2.4 fold, p= 0.02, respectively). Considering that CD164 is expressed in skinresiding CD4+ T 
cells, this result is different from pattern of CD164 expression in circulating CD4+ T cells, where 
CD164 expression is restricted to Sézary syndrome, a leukemic variant of CTCL but not MF, atopic 
dermatitis, or psoriasis patients [14, 43]. The presence of CD164 expression in skin of psoriatic 
patients is suggestive of some common pathways operational in the skin manifestations of these 
diseases, but this remains to be established. 
Our results also suggest the likely existence of an association between T plastin and CD164 in 
patients’ skinresiding CD4+ T cells, similar to circulating malignant CD4+ T cells, as mRNAs for both 
CD164 and T plastin are present in skin lesions from SS and MF patients. 
Our data show that B1–B0 patients do not demonstrate a fully developed malignant status identified 
by the presence of Sézary signature phenotype, high expression of FCRL3, and miR-214 that is 
apparent in B2 patients. In B1–B0 patients, T plastin, FCRL3, and miR-214 are expressed in some 
patients, predominantly in CD164+ CD4+ T cells. However, the levels are low, and the differences 
between CD164+ and CD164- populations are not significant due to high variability in expression of 
these genes between the patients. Similarly, STAT-4 and Gata-3 expression in CD164+CD4+ T cells 
is not significantly different from that in CD164-CD4+ T cells. It is noticeable that overall, levels of 
STAT-4 expression in B1–B0 patients are higher than those in B2 patients, whereas Gata-3 
expression is comparable to the levels observed in normal controls. However, Tox, which is highly 
expressed in B2 patients, is also highly expressed in B1–B0 patients, and its expression is 
significantly higher (2.9 fold) in CD164+CD4+ T cells compared with CD164-CD4+ T cells. Our 
results point to an important observation; the significant expression of Tox predominantly in 
CD164+CD4+ T cells from B1 to B0 patients strongly suggests that Tox may be one of the early 
transcription factors associated with malignant transformation in CD164+CD4+ T cells in SS patients. 
Its high expression in CD4+ T cells and in the skin from SS patients, in conjunction with the 
expression of CD164 and other clinical data, may aid in specific diagnosis of SS [11]. 
Our data demonstrate that CD164+CD4+ T cells are the population that predominantly expresses 
genes linked with malignancy and poor prognosis. However, particularly in B2 patients, CD164-CD4+ 
T cells also express the Sézary signature phenotype as well as FCRL3, Tox, and miR-214, but at 
significantly lower levels compared to CD164+CD4+ T cells. The level of gene expression in the 
CD164population appears to depend upon circulating tumor burden; the highest expression is found 
in patients with the highest percentage of circulating CD4+ T cells bearing a single TCRVβ. The study 
of Guenova et al. [15] showed that in the presence of malignant cells, benign CD4+ T cells from SS 
patients acquire a Th2 biased phenotype, including elevated GATA-3 expression that could be 
reversed by separating malignant and benign CD4+ T cells. This study implies that the phenotype of 
CD164-CD4+ T cells in patients is influenced by the presence of pathogenic CD164+CD4+ T cells and 
factor(s) released by these cells. A high percentage of malignant cells may correspond to a high 
concentration of factor(s) influencing the phenotype of benign cells. This may explain the highly 
reduced STAT-4 expression in CD164-CD4+ T cells from B2 patients compared with close to normal 
expression of STAT-4 in CD164-CD4+ T cells from B1 patients. It is also possible that some of 
CD164-CD4+ T cells are normal T cells activated by malignant cells, and as such, they may express 
various molecules, including T plastin or miR214, that have been shown to be upregulated in 
activated T cells [4, 20]. Whether the expression of malignancy associated genes in CD164-CD4+ T 
cells results from the direct effect of factor(s) triggering malignant transformation or results from 
factor(s) released by CD164+CD4+ malignant T cells, remains to be established. 
 In support of our results indicating CD164 as an important marker for malignant cells in CTCL, 
elevated CD164 expression has been associated with several human cancers, including prostate, 
ovarian, colon, and breast carcinoma. It has also been identified as a new marker for acute 
lymphoblastic leukemia [10, 16, 17, 24, 40]. 
In summary, our results show that CD164 is expressed predominantly on CD4+ T cells expressing 
genes linked to malignancy and poor prognosis in Sézary syndrome patients. A well-defined Sézary 
signature phenotype and the expression of FCRL-3, Tox, and miR-214 are significantly associated 
with CD164+ rather than with CD164-CD4+ T cells. The high expression of miR-214 in CD164+CD4+ 
T cells deserves further study as miR-214 contributes to cancer formation and progression by 
affecting several signaling pathways and is controlled by transcription factor Twist 1, reported to be 
highly expressed in SS patients’ CD4+ T cells [35, 45]. Our results also show that CD164 is co-
expressed with KIR3DL2 on CD4+ T cells from a majority of SS patients with advanced B2 disease. 
Assessing the expression of both markers can be useful in the diagnosis of Sézary syndrome and 
monitoring of the disease, particularly in patients, whose TCRVβ cannot be defined by the existing 
panel of antibodies. However, as our data show, B1–B0 patients do not consistently express 
KIR3DL2; therefore, the increased expression of CD164, along with the expression of Tox, could be 
the first indication of malignant transformation. 
Our studies represent one of the first attempts to use a surface biomarker, such as CD164, to isolate 
malignant cells and characterize their phenotype in detail. Given the heterogeneous nature of the 
disease and variability among patients, potentially more markers will be discovered allowing for the 
precise identification of the phenotype of malignant cells, facilitating earlier diagnosis and the 
monitoring of disease progression, but may also provide a means for discovering new therapeutic 
targets. 
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Figure legends 
 
Fig. 1 
CD164+CD4+ T cells from Sézary syndrome patients are the predominant population 
expressing the Sézary signature phenotype and significantly upregulated expression of FCRL3 
and Tox. PBMC from high tumor burden SS patients diagnosed as B2, upper panel (with ≥50 % 
of CD26− CD164+CD4+ T cells, n = 15, left graph), and PBMC from medium-to-low tumor 
burden patients diagnosed as B1–B0, lower panel (with ≤50 % CD26− CD164+CD4+ T cells, 
n = 9, left graph), were sorted into CD164+/CD164−CD4+ T cells. Each population was 
assessed for the expression of mRNA for T plastin, GATA-3, STAT-4, FCRL3, and Tox by 
qRT-PCR. CD4+ T cells isolated from PBMC of healthy donors (n = 9, pooled) were used as 
controls. Graphs show relative expression of given mRNA in CD164+ and in CD164−CD4+ T 
cells. Error bars represent mean ± SEM. The nonparametric Wilcoxon signed-rank test was 
used to assess differences between groups. P values ***<0.0005; **<0.005; *<0.05 
Fig. 2 
CD164 mRNA is expressed in skin from Sézary syndrome and mycosis fungoides patients. 
Skin samples from seven Sézary syndrome patients (SS), nine mycosis fungoides patients 
(MF), four atopic dermatitis patients (AD), three psoriasis patients (PS), and nine healthy 
controls (HC) were examined for the expression of the genes by qRT-PCR. Fold difference for 
CD164 was calculated versus expression levels in skin from healthy controls. Error bars 
represent mean ± SEM. Unpaired t test used to assess differences. P values ***<0.0005; 
**<0.005; *<0.05 
 
 Fig. 3 
CD164 is expressed on the cell surface of skin-resident CD4+ T cells from Sézary syndrome 
patients. a Percentage of CD164+CD4+ T cells isolated from skin of 5 Sézary syndrome patients 
(SS) and 11 healthy controls (HC) analyzed by flow cytometry. Error bars represent 
mean ± SEM. P value *<0.05. b Representative histogram illustrating CD164 expression on 
CD4+ T cells isolated from skin of SS patient (left panel) and healthy control (right panel) 
Fig. 4 
MicroRNA-214 is mainly expressed in CD164+CD4+ T cells from Sézary syndrome patients. 
CD4+ T cells from B2 patients (a, n = 17) and from B1 to B0 patients (b, n = 8) were assessed 
for the expression of miR-214 by qRT-PCR. The expression of miR-214 was subsequently 
assessed in sorted CD164+/CD164−CD4+ T cells from B2 patients (c, n = 15). Error bars 
represent mean ± SEM. P values **<0.005 
Fig. 5 
CD164 and KIR3DL2 are co-expressed on CD4+ T cells from Sézary syndrome patients. 
PBMC from patients diagnosed as B2 (a, n = 31) and B1–B0 (b, n = 10) were gated on 
CD3+/CD4+ T cells and analyzed for the expression of KIR3DL2, CD164, and CD26 by flow 
cytometry. Graphs show percentage of CD4+ T cells from each patient expressing these 
molecules. c CD164 and KIR3DL2 are co-expressed on CD4+ T cells from SS patient 
diagnosed with advanced B2 disease. Error bars represent mean ± SEM 
 
